Moloxin (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA supercoiling and replication. By blocking these targets, the drug prevents bacterial DNA synthesis and transcription, leading to rapid bacterial cell death and a concentration‑dependent bactericidal effect.

The specific dose and infusion rate of Moloxin are determined by the prescribing clinician based on the infection being treated, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the product label and institutional protocols when prescribing.

Safety of moxifloxacin during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To request Moloxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Moloxin (moxifloxacin) offers a broader spectrum against atypical respiratory pathogens compared with older fluoroquinolones such as levofloxacin, and it has a higher potency against Gram‑positive organisms. However, both belong to the fluoroquinolone class and share similar safety considerations, so selection depends on local resistance patterns and patient factors.

Moloxin for injection must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and do not freeze or shake the product. Once removed from refrigeration, use within the time frame specified in the label and follow aseptic techniques for preparation.

Moloxin is administered by intravenous infusion. The exact infusion rate and duration are determined by the prescribing clinician, typically based on the infection severity and patient characteristics. Administration should be performed by qualified healthcare personnel using aseptic technique.

Serious risks include tendon rupture (especially in older adults or those on corticosteroids), QT interval prolongation that can lead to cardiac arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for these events.

Moloxin should be avoided in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals taking medications that significantly prolong the QT interval unless benefits outweigh risks. Caution is also advised in patients with severe renal or hepatic impairment.